Recruiting
A Study to Evaluate the Drug-drug Interaction Potential of BMS-986196 in Healthy Participants - IM038-022
Updated:
18 July, 2023
|
ClinicalTrials.gov
Print Friendly Summary
Trial Details
Phase
Gender(s)
Age Range
Location(s)
Recruiting
Treatment Options
Inclusion Criteria: - Healthy male and female participants as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations. - Body mass index of 18.0 to 33.0 kilogram per meter squared (kg/m^2), inclusive, and body weight ≥50.0 kg. Exclusion Criteria: - History of rhabdomyolysis. - History of peptic ulcer disease or significant GI bleeding. - History of malignancy in the 5 years prior to screening (except fully excised basal cell carcinoma).
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information